Brighton Jones LLC Buys New Position in West Pharmaceutical Services, Inc. $WST

Brighton Jones LLC acquired a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the 3rd quarter, Holdings Channel reports. The fund acquired 2,514 shares of the medical instruments supplier’s stock, valued at approximately $660,000.

Several other institutional investors also recently bought and sold shares of WST. SYM FINANCIAL Corp lifted its position in shares of West Pharmaceutical Services by 5.1% during the 2nd quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock valued at $225,000 after buying an additional 50 shares in the last quarter. Benjamin Edwards Inc. lifted its holdings in West Pharmaceutical Services by 1.7% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock worth $661,000 after buying an additional 50 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of West Pharmaceutical Services by 4.0% during the second quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier’s stock worth $288,000 after buying an additional 51 shares in the last quarter. MJP Associates Inc. ADV raised its stake in West Pharmaceutical Services by 2.7% in the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier’s stock valued at $431,000 after buying an additional 52 shares in the last quarter. Finally, Pallas Capital Advisors LLC lifted its position in shares of West Pharmaceutical Services by 1.0% during the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock worth $1,386,000 after buying an additional 62 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 0.3%

Shares of NYSE WST opened at $276.66 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $348.90. The company has a market cap of $19.90 billion, a price-to-earnings ratio of 40.99, a P/E/G ratio of 4.13 and a beta of 1.17. The business has a fifty day simple moving average of $275.16 and a 200-day simple moving average of $253.60.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. During the same quarter last year, the business posted $1.85 EPS. West Pharmaceutical Services’s revenue was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th will be issued a dividend of $0.22 per share. The ex-dividend date is Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is currently 13.04%.

Wall Street Analyst Weigh In

WST has been the subject of several recent research reports. Barclays increased their target price on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research note on Monday, October 27th. Cowen initiated coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They set a “buy” rating on the stock. Redburn Partners set a $311.00 price objective on West Pharmaceutical Services in a report on Monday, September 15th. KeyCorp increased their target price on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, October 24th. Finally, Wall Street Zen upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, December 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $342.20.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.